| Carla A Keahey, ACNS, FNP | |
|
1755 48th St Ste 200, Boulder, CO 80301 | |
| (303) 415-7450 | |
| (303) 494-5265 |
| Full Name | Carla A Keahey |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 18 Years |
| Location | 1755 48th St Ste 200, Boulder, Colorado |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750442323 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SA2200X | Clinical Nurse Specialist - Adult Health | APN.0992283-CNS (Colorado) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | APN.0994429-NP (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Boulder Community Health | Boulder, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Boulder Community Health | 6800707233 | 212 |
News Archive
A new study reports long-lasting, effective protection against severe disease with the AZD7442 antibody cocktail.
Ontario's doctors are congratulating Albany County, New York for passing a law that requires chain restaurants with ten or more locations nationally to post the calorie counts of items on their menus and menu boards. The Ontario Medical Association (OMA) is calling for similar legislation to be introduced in Ontario.
A bacterial protein fragment instigates lung tissue death in pulmonary fibrosis, a mysterious disease affecting millions of people worldwide, according to a new study from researchers at the University of Illinois at Urbana-Champaign and Mie University in Japan.
Elusys Therapeutics and Lonza today announced an agreement for the scale-up and commercial production of Anthim, a therapeutic monoclonal antibody in late-stage development for the treatment of inhaled anthrax. Under the new contract, Lonza will provide process scale-up, technology transfer, validation, and commercial manufacturing at one of its facilities in the USA. The manufacturing process for Anthim was optimized for full scale production by Lonza under a separate agreement announced in 2009.
Results of the NRG Oncology clinical trial NRG-HN002 indicated that the combination of intensity-modulated radiotherapy (IMRT) and cisplatin was able to meet acceptability criteria for progression-free survival (PFS) and swallowing-related quality of life for patients who have p16-positive, non-smoking-associated oropharyngeal cancer.
› Verified 5 days ago
| Entity Name | Boulder Community Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821074196 PECOS PAC ID: 6800707233 Enrollment ID: O20040123000284 |
News Archive
A new study reports long-lasting, effective protection against severe disease with the AZD7442 antibody cocktail.
Ontario's doctors are congratulating Albany County, New York for passing a law that requires chain restaurants with ten or more locations nationally to post the calorie counts of items on their menus and menu boards. The Ontario Medical Association (OMA) is calling for similar legislation to be introduced in Ontario.
A bacterial protein fragment instigates lung tissue death in pulmonary fibrosis, a mysterious disease affecting millions of people worldwide, according to a new study from researchers at the University of Illinois at Urbana-Champaign and Mie University in Japan.
Elusys Therapeutics and Lonza today announced an agreement for the scale-up and commercial production of Anthim, a therapeutic monoclonal antibody in late-stage development for the treatment of inhaled anthrax. Under the new contract, Lonza will provide process scale-up, technology transfer, validation, and commercial manufacturing at one of its facilities in the USA. The manufacturing process for Anthim was optimized for full scale production by Lonza under a separate agreement announced in 2009.
Results of the NRG Oncology clinical trial NRG-HN002 indicated that the combination of intensity-modulated radiotherapy (IMRT) and cisplatin was able to meet acceptability criteria for progression-free survival (PFS) and swallowing-related quality of life for patients who have p16-positive, non-smoking-associated oropharyngeal cancer.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Carla A Keahey, ACNS, FNP Po Box 9049, Boulder, CO 80301-9049 Ph: (303) 415-7450 | Carla A Keahey, ACNS, FNP 1755 48th St Ste 200, Boulder, CO 80301 Ph: (303) 415-7450 |
News Archive
A new study reports long-lasting, effective protection against severe disease with the AZD7442 antibody cocktail.
Ontario's doctors are congratulating Albany County, New York for passing a law that requires chain restaurants with ten or more locations nationally to post the calorie counts of items on their menus and menu boards. The Ontario Medical Association (OMA) is calling for similar legislation to be introduced in Ontario.
A bacterial protein fragment instigates lung tissue death in pulmonary fibrosis, a mysterious disease affecting millions of people worldwide, according to a new study from researchers at the University of Illinois at Urbana-Champaign and Mie University in Japan.
Elusys Therapeutics and Lonza today announced an agreement for the scale-up and commercial production of Anthim, a therapeutic monoclonal antibody in late-stage development for the treatment of inhaled anthrax. Under the new contract, Lonza will provide process scale-up, technology transfer, validation, and commercial manufacturing at one of its facilities in the USA. The manufacturing process for Anthim was optimized for full scale production by Lonza under a separate agreement announced in 2009.
Results of the NRG Oncology clinical trial NRG-HN002 indicated that the combination of intensity-modulated radiotherapy (IMRT) and cisplatin was able to meet acceptability criteria for progression-free survival (PFS) and swallowing-related quality of life for patients who have p16-positive, non-smoking-associated oropharyngeal cancer.
› Verified 5 days ago
Mollie Marie Babich, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1900 Wardenburg Drive, Boulder, CO 80309 Phone: 303-492-2277 | |
Linda Lea Johnson, WHNP, M.S.N. Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2855 Valmont Rd, Boulder, CO 80301 Phone: 303-440-9320 Fax: 303-440-9320 | |
Mrs. Barbara Jo Franklin, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 805 S Broadway St Ste 103, Boulder, CO 80305 Phone: 303-835-9523 | |
Ian Villanueva, DNP, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1900 Wardenburg Drive, Boulder, CO 80309 Phone: 314-499-8625 | |
Abbey Stone, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 6666 Gunpark Dr, Boulder, CO 80301 Phone: 303-578-8085 | |
Sally Thomas Lowell, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2525 13th St, Boulder, CO 80304 Phone: 303-449-6050 | |
Kolby Sands, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2760 29th St Ste 2b, Boulder, CO 80301 Phone: 303-440-6400 |